Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy investigated in the ZUMA-1 trial – is the first chimeric antigen receptor (CAR) T-cell therapy recommended for ...

New research shows that GD2 CAR-T cell therapy offers a potential cure for neuroblastoma, with some patients achieving long-term remission for over a decade—marking a major milestone in solid ...

Like other CAR-Ts, Calibr's therapy is manufactured from a patient's own T-cells, which are harvested and genetically modified to fight cancer before being reintroduced into the body.

Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma. Various factors play a role in whether or not a patient is ...

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent the longest reported remission to date in a patient treated with chimeric ...

And it is at this intersection that the future of medicine is being written, with innovations like CRISPR and CAR-T therapy unlocking ... adapted it as a tool to cut, delete, or add DNA sequences ...

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust ... immunosuppressants and steroids as of the data cut-off date. As for dermatomyositis (DM), the ...

A heated exchange unfolded online as tech billionaire Elon Musk and Polish Foreign Minister Radoslaw ... Musk remains firm in his decision not to cut off Ukraine’s access to his satellite ...

NEW car dealers have been thrown a major lifeline as the Government has acted on their complaints that the 100 per cent bond they pay on duties ties up too much of their working capital.